论文部分内容阅读
目的观察布地奈德雾化吸入治疗慢性阻塞性肺疾病(COPD)急性加重期的疗效。方法选择45例COPD急性加重期患者,随机分为治疗组23例,对照组22例。同时给予常规治疗,治疗组雾化吸入布地奈德2mg/次,每8h1次。对照组给予口服甲泼尼龙片24mg/次,1次/d。结果治疗前后对比,治疗组和对照组患者治疗后FEV1、PaO2、PaCO2呼吸困难评分改善值差异有统计学意义(P<0.05),两组间比较差异无统计学意义,治疗组不良反应发生率明显低于对照组。结论布地奈德溶液雾化治疗与口服糖皮质激素疗效相近,副作用少,安全性好,是重度COPD急性加重期糖皮质激素的有效选择。
Objective To observe the efficacy of inhaled budesonide in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Forty-five patients with acute exacerbation of COPD were randomly divided into treatment group (n = 23) and control group (n = 22). At the same time give conventional treatment, the treatment group inhaled budesonide 2mg / time, every 8h1 times. The control group was given oral methylprednisolone tablets 24mg / time, 1 time / d. Results Before and after treatment, there was significant difference in improvement of FEV1, PaO2, PaCO2 dyspnea score after treatment between the two groups (P <0.05), the difference between the two groups was not statistically significant, the incidence of adverse reactions in the treatment group Obviously lower than the control group. Conclusions Budesonide solution nebulization is similar to oral glucocorticoid, with few side effects and good safety. It is an effective choice for glucocorticoid in acute exacerbation of COPD.